Medivolve Inc. (MEDV.NE)
| Previous Close | 0.0200 |
| Open | 0.0200 |
| Bid | 0.0100 x N/A |
| Ask | 0.0150 x N/A |
| Day's Range | 0.0150 - 0.0200 |
| 52 Week Range | 0.0150 - 0.1450 |
| Volume | |
| Avg. Volume | 1,498,271 |
| Market Cap | 5.869M |
| Beta (5Y Monthly) | 2.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3770 |
| Earnings Date | Nov 14, 2022 - Nov 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Aberdeen Disposes of Shares of Medivolve and Ceases to Be an Insider
TORONTO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- ABERDEEN INTERNATIONAL INC. (“Aberdeen” or the “Company”) (TSX: AAB) announces that it has sold 7,000,000 common shares of Medivolve Inc. (“Medivolve”) (NEO: MEDV) on September 22, 2022, which has resulted in Aberdeen’s ownership being reduced by 1.7% to less than 10% of the outstanding Medivolve common shares and Aberdeen ceasing to be an insider of Medivolve The Company reviews its holdings from time to time and may increase or decrease its position
- GlobeNewswire
Medivolve Announces Launch of Investor Awareness Campaign and Refiling of Q2 2022 Financial Statements
TORONTO, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Medivolve Inc. (“Medivolve” or the “Company”) (NEO: MEDV; OTC: COPRF; FRA: 4NC) is pleased to announce the launch of an investor marketing campaign to raise awareness of the Company in the investing community. The Company also announces that it has amended and refiled its condensed interim consolidated financial statements (the “Q2 2022 Financials”) and corresponding management’s discussion and analysis (the “Q2 2022 MDA”) for the six-month period ended
- GlobeNewswire
Medivolve Announces Q2 2022 Financial Results
TORONTO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Medivolve Inc. (“Medivolve” or the “Company”) (NEO: MEDV; OTC: COPRF; FRA: 4NC), a healthcare technology company that seeks to improve the US healthcare system by leveraging a bespoke telehealth platform, clinical diagnostic network, and data driven AI to improve patient care, today announced financial results for the second quarter ended June 30, 2022. "Medivolve delivered another strong quarter of financial results, achieving a 72% increase in revenue
